Prostate Cancer

The FDA has accepted a supplemental new drug application and granted priority review to darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.

Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.

Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.

Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.

Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.

Helen Heng-Shan Moon, MD, discusses the role of PARP inhibitors in prostate cancer.

A detailed review of the available pharmacologic agents used to treat patients with metastatic castration-resistant prostate cancer.

A brief discussion on how novel imaging strategies are being used to inform the treatment of patients with prostate cancer.

The FDA has cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer.

A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].

A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

High genomic loss of heterozygosity scores may serve as a predictive marker for response to treatment with talazoparib in metastatic castration-resistant prostate cancer.

The genetic adjustment of prostate-specific antigen could reduce over-diagnosis, de-escalate invasive testing, and improve the detection of aggressive disease in patients with prostate cancer.

Prostate cancer is the most common cancer in men and the second-leading cause of cancer-related deaths in men in the US.

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.

Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.

Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.

The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.

Axel S. Merseburger, MD, discusses the safety and efficacy results from the phase 3b PRESIDE trial examining continued enzalutamide treatment with docetaxel in select patients with metastatic castration-resistant prostate cancer who had progressed on enzalutamide monotherapy and the significance of the data for the treatment paradigm.